Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
72 hedge funds and large institutions have $242M invested in Kindred Biosciences, Inc. in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 19 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less funds holding
Funds holding: 81 → 72 (-9)
23% less capital invested
Capital invested by funds: $314M → $242M (-$72.6M)
32% less call options, than puts
Call options by funds: $89K | Put options by funds: $130K
47% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.14M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$1.97M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.92M |
| 4 |
SAM
Silverback Asset Management
Chapel Hill,
North Carolina
|
+$1.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$4.35M |
| 2 |
New York State Common Retirement Fund
Albany,
New York
|
-$2.95M |
| 3 |
AI
Ariel Investments
Chicago,
Illinois
|
-$2.26M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.25M |
| 5 |
AFS
Amtrust Financial Services
New York
|
-$1.22M |
KIN Hedge Fund Activity: Q4 2018 in Review
72 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q4 2018, worth a combined $242M — down 23% from $314M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KIN and 10 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 27 added.
The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $2.14M. The largest seller was Morgan Stanley, cutting an estimated $4.35M.
- 72 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q4 2018, down from 81 in Q3 2018.
- Funds reported $242M of Kindred Biosciences, Inc. stock for Q4 2018, down 23% quarter-over-quarter.
- 10 funds opened new Kindred Biosciences, Inc. positions in Q4 2018 and 19 closed out, a net change of -9 holders.
- The largest Kindred Biosciences, Inc. buyer in Q4 2018 was Assenagon Asset Management, an estimated $2.14M added.
- The largest Kindred Biosciences, Inc. seller in Q4 2018 was Morgan Stanley, an estimated $4.35M sold.
Based on aggregated 13F filings for Q4 2018.